Results 131 to 140 of about 1,741 (166)
Some of the next articles are maybe not open access.
Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Tezspire be reimbursed by public drug plans as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery if certain conditions are met. The Canadian Drug
openaire +1 more source
Canada’s Drug Agency (CDA-AMC) recommends that Tezspire be reimbursed by public drug plans as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery if certain conditions are met. The Canadian Drug
openaire +1 more source
TSLP and Nasal Epithelium: A Missing Link in Tezepelumab's Mechanism
International Forum of Allergy & RhinologyNo abstract is available for this article.
Fieux, Maxime +6 more
openaire +2 more sources
Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
International Journal of Molecular Sciences, 2021Alessandro Vatrella +2 more
exaly
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy
Journal of Allergy and Clinical Immunology: in Practice, 2021Jonathan Corren +2 more
exaly
Is tezepelumab the ubiquitous biologic for severe asthma?
The Lancet Respiratory Medicine, 2023Beasley, Richard, Chang, Anne B.
openaire +4 more sources
Tezepelumab in the Treatment of Uncontrolled Severe Asthma
Annals of Pharmacotherapy, 2023Pramodini Kale-Pradhan, Melissa Lipari
exaly